Skadden, Arps, Slate, Meagher & Flom is advising Japan’s Otsuka Pharmaceutical Co. Ltd. on its proposed $886 million acquisition of Dublin, Calif.-based Astex Pharmaceuticals Inc.

Astex is known for its cancer treatments. Otsuka is seeking to expand its own oncology portfolio and research and development capabilities in the space.